BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanazawa T, Misawa K, Fukushima H, Misawa Y, Sato Y, Maruta M, Imayoshi S, Kusaka G, Kawabata K, Mineta H, Carey TE, Nishino H. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis. Oncol Lett 2018;15:9043-50. [PMID: 29805635 DOI: 10.3892/ol.2018.8525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sánchez ML, Coveñas R. The Galaninergic System: A Target for Cancer Treatment. Cancers 2022;14:3755. [DOI: 10.3390/cancers14153755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Gu S, Qian S, Lin S, Ye D, Li Q, Yang J, Ying X, Li Z, Tang M, Wang J, Chen K, Jin M. Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis. J Hum Genet 2022. [PMID: 35606503 DOI: 10.1038/s10038-022-01038-9] [Reference Citation Analysis]
3 Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sørensen M. HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:693394. [PMID: 34249747 DOI: 10.3389/fonc.2021.693394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Wang SC, Liao LM, Ansar M, Lin SY, Hsu WW, Su CM, Chung YM, Liu CC, Hung CS, Lin RK. Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of GCM2, ITPRIPL1 and CCDC181 for Detection of Early Breast Cancer and Surgical Treatment Response. Cancers (Basel) 2021;13:1375. [PMID: 33803633 DOI: 10.3390/cancers13061375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Misawa K, Kanazawa T, Mochizuki D, Imai A, Mima M, Yamada S, Morita K, Misawa Y, Shinmura K, Mineta H. Genes Located on 18q23 Are Epigenetic Markers and Have Prognostic Significance for Patients with Head and Neck Cancer. Cancers (Basel) 2019;11:E401. [PMID: 30901947 DOI: 10.3390/cancers11030401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]